A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 08 Mar 2018 Planned End Date changed from 14 May 2018 to 16 Jul 2018.
- 08 Mar 2018 Planned primary completion date changed from 30 Apr 2018 to 16 Jul 2018.
- 28 Aug 2017 Planned End Date changed from 18 Oct 2017 to 14 May 2018.